drugset / Trial / NCT07043946
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
Non-randomizedSequentialOpen-labelTreatment
Summary
The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
Timeline
- Start
- 2025-06-30
- Primary completion
- 2027-08
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budoprutug | Monoclonal antibody | — | Intravenous |